名前: ラロキシフェン
CAS番号: 84449-90-1
方式: C28H27NO4S
分子量: 473.58
同義語: ケオキシフェン;LY 139481;[2-(4-ヒドロキシフェニル)-6-ヒドロキシベンゾ[b]チエン-3-イル][4-(2-(1-ピペリジニル)エトキシ)フェニル]メタノン;
密度: 1.289 g/cm3
融点: 250-253 ℃
沸点: 728.2 °Cで 760 mmHg
引火点: 394.2 ℃
溶解性: DMSO: 28 mg/mL, 溶ける
外観: 薄黄色の固体
使用法 : 非ステロイド性エストロゲン受容体混合アゴニスト/アンタゴニスト
ラロキシフェン, a member of the class of selective estrogen receptor modulators (SERM), reproduces the beneficial effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium.
This is a review article summarizing its mechanism, effects on bone and its applicability in traumatology clinical practice. In postmenopausal osteoporosis, this drug has been proven to decrease accelerated bone turnover, increase bone mineral density (BMD), and to structurally recover bone, decreasing the risk of vertebral fractures and the risk of non-vertebral fractures in patients with previous, severe vertebral fractures.
Raloxifene may increase your risk of a blood clot in your leg, your lung, or your eye.You should not take raloxifene if you have ever had this type of blood clot.
Raloxifene can also increase your risk of a stroke, which can be fatal. This risk is highest if you have certain risk factors (such as smoking, having heart problems or high blood pressure, or if you have ever had a heart attack or a stroke).
Although this medicine is for use only in postmenopausal women, you should not take raloxifene if you are pregnant or breastfeeding.
| ITEMS |
SPECIFICATION |
RESULT |
| 外観 |
白 &off-white powder |
適合 |
| 学年 |
Anti Estrogen Steroids |
適合 |
| 溶解性 |
Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water |
適合 |
| Identifications |
Infrared Absorption |
適合 |
| 乾燥減量 |
≤0.5% |
0.4% |
| 着火残留物 |
≤0.1% |
0.06% |
| ヘビーメタル |
≤10ppm |
適合 |
| Raloxifene Impurity1 |
≤0.20 % |
0.10% |
| Any unspecified individual impurity 2 |
≤0.10% |
Max. 0.08% |
| 総不純物 |
≤0.50% |
0.40% |
| ラロキシフェン |
≧98.0% |
99.0% |
